SCHEMBL1748575

SCHEMBL1748575

COc1cc2c(-c3cc4cccnc4[nH]3)cn(C)c2cc1OCC(=O)N1CCOCC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.68
SYK P43405 1/20 0.49
RIPK1 Q13546 1/20 0.47
HTT P42858 1/20 0.44
ALDH1A1 P00352 4/20 0.44
EPHA2 P29317 1/20 0.43
KDR P35968 1/20 0.43
EPHB4 P54760 1/20 0.43
HPGD P15428 3/20 0.41
KDM4E B2RXH2 2/20 0.41
HSD17B10 Q99714 2/20 0.41
GAA P10253 2/20 0.41
MAPK1 P28482 2/20 0.41
GLA P06280 1/20 0.41
KLK7 P49862 1/20 0.41
CCNT1 O60563 1/20 0.41
CDK9 P50750 1/20 0.41
MAPT P10636 3/20 0.41
TP53 P04637 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1749017 0.92 IGF1R (0.70) IGF1RSYKRIPK1GAAMAPK1
SCHEMBL1748773 0.89 IGF1R (0.66) IGF1RSYKRIPK1GAAMAPK1
SCHEMBL1748512 0.86 IGF1R (0.62) IGF1RSYKRIPK1TP53
SCHEMBL1748730 0.86 IGF1R (0.59) IGF1RSYKRIPK1HTTALDH1A1
SCHEMBL12606279 0.86 SYK (0.55) IGF1RSYKRIPK1ALDH1A1HPGD
SCHEMBL1778705 0.86 IGF1R (0.58) IGF1RSYKRIPK1ALDH1A1CCNT1
SCHEMBL1749103 0.86 IGF1R (0.80) IGF1RSYKRIPK1CDK9
SCHEMBL1748777 0.85 IGF1R (0.73) IGF1RSYKEPHA2KDREPHB4
SCHEMBL6139727 0.84 IGF1R (0.55) IGF1RSYKRIPK1ALDH1A1CDK9
SCHEMBL1780899 0.83 IGF1R (1.00) IGF1RSYKRIPK1KDRCDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US claimed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US claimed
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885SYK 379/4885RIPK1 392/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885SYK 379/4885RIPK1 392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.